[{"indications": "Indications\u00a0respiratory-tract infections, mild to moderate skin and soft-tissue\r\ninfections, otitis media; Lyme disease (see also section 5.1.1.3); prevention of pertussis (Table\r\n2, section 5.1); Helicobacter pylori eradication (section 1.3)", "name": "CLARITHROMYCIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.5 Macrolides"], "cautions": "Cautions\u00a0\n(From 5.1.5 Macrolides: British National Formulary)\nOral infections\u00a0The macrolides are an alternative for oral infections in penicillin-allergic patients or where a beta-lactamase producing organism is involved. However, many organisms are now resistant to macrolides or rapidly develop resistance; their use should therefore be limited to short courses. Metronidazole (section 5.1.11) may be preferred as an alternative to a penicillin.Cautions\u00a0Macrolides should be used with caution in patients with a predisposition to QT interval prolongation (including electrolyte disturbances and concomitant use of drugs that prolong the QT interval). Macrolides may aggravate myasthenia gravis. ; interactions: Appendix 1 (macrolides)", "side-effects": "Side-effects\u00a0\n(From 5.1.5 Macrolides: British National Formulary)\nSide-effects\u00a0Nausea, vomiting, abdominal discomfort, and diarrhoea are the most common side-effects of the macrolides, but they are mild and less frequent with azithromycin and clarithromycin than with erythromycin. Hepatotoxicity (including cholestatic jaundice) and rash occur less frequently. Other side-effects reported rarely or very rarely include pancreatitis, antibiotic-associated colitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Generally reversible hearing loss (sometimes with tinnitus) has been reported after large doses of a macrolide; it occurs commonly after long-term therapy with azithromycin. Intravenous infusion may cause local tenderness and phlebitis.; also\r\ndyspepsia, tooth and tongue discoloration, smell and taste disturbances,\r\nstomatitis, glossitis, and headache; less commonly arthralgia and myalgia; rarely tinnitus; very rarely dizziness, insomnia, nightmares, anxiety, confusion,\r\npsychosis, paraesthesia, convulsions, hypoglycaemia, renal failure,\r\ninterstitial nephritis, leucopenia, and thrombocytopenia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3861.htm", "doses": ["By mouth, adult and child over 12 years, 250\u00a0mg every\r\n12 hours for 7 days, increased in pneumonia or severe infections to\r\n500\u00a0mg every 12 hours for up to 14 days (see also Table 1, section 5.1); child body-weight under 8\u00a0kg, 7.5\u00a0mg/kg twice daily; 8\u201311\u00a0kg, 62.5\u00a0mg\r\ntwice daily; 12\u201319\u00a0kg, 125\u00a0mg twice daily; 20\u201329\u00a0kg, 187.5\u00a0mg twice\r\ndaily; 30\u201340\u00a0kg, 250\u00a0mg twice daily", "Lyme disease (see also section 5.1.1.3), adult and child over 12 years, 500\u00a0mg every\r\n12 hours for 14\u201321 days [unlicensed duration]; child 1 month\u201312 years see BNF for Children", "By intravenous infusion into larger\r\nproximal vein, adult and child over 12 years, 500\u00a0mg twice daily; child 1 month\u201312 years see BNF for Children"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless potential benefit\r\noutweighs risk"}, {"indications": "Indications\u00a0respiratory-tract infections, mild to moderate skin and soft-tissue\r\ninfections, otitis media; Lyme disease (see also section 5.1.1.3); prevention of pertussis (Table\r\n2, section 5.1); Helicobacter pylori eradication (section 1.3)", "name": "CLARITHROMYCIN Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.1 Antibacterial drugs", "5.1.5 Macrolides", "CLARITHROMYCIN", "Modified release"], "cautions": "Cautions\u00a0\n(From 5.1.5 Macrolides: British National Formulary)\nOral infections\u00a0The macrolides are an alternative for oral infections in penicillin-allergic patients or where a beta-lactamase producing organism is involved. However, many organisms are now resistant to macrolides or rapidly develop resistance; their use should therefore be limited to short courses. Metronidazole (section 5.1.11) may be preferred as an alternative to a penicillin.Cautions\u00a0Macrolides should be used with caution in patients with a predisposition to QT interval prolongation (including electrolyte disturbances and concomitant use of drugs that prolong the QT interval). Macrolides may aggravate myasthenia gravis. ; interactions: Appendix 1 (macrolides)", "side-effects": "Side-effects\u00a0\n(From 5.1.5 Macrolides: British National Formulary)\nSide-effects\u00a0Nausea, vomiting, abdominal discomfort, and diarrhoea are the most common side-effects of the macrolides, but they are mild and less frequent with azithromycin and clarithromycin than with erythromycin. Hepatotoxicity (including cholestatic jaundice) and rash occur less frequently. Other side-effects reported rarely or very rarely include pancreatitis, antibiotic-associated colitis, QT interval prolongation, arrhythmias, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Generally reversible hearing loss (sometimes with tinnitus) has been reported after large doses of a macrolide; it occurs commonly after long-term therapy with azithromycin. Intravenous infusion may cause local tenderness and phlebitis.; also\r\ndyspepsia, tooth and tongue discoloration, smell and taste disturbances,\r\nstomatitis, glossitis, and headache; less commonly arthralgia and myalgia; rarely tinnitus; very rarely dizziness, insomnia, nightmares, anxiety, confusion,\r\npsychosis, paraesthesia, convulsions, hypoglycaemia, renal failure,\r\ninterstitial nephritis, leucopenia, and thrombocytopenia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/60385.htm", "doses": ["By mouth, adult and child over 12 years, 250\u00a0mg every\r\n12 hours for 7 days, increased in pneumonia or severe infections to\r\n500\u00a0mg every 12 hours for up to 14 days (see also Table 1, section 5.1); child body-weight under 8\u00a0kg, 7.5\u00a0mg/kg twice daily; 8\u201311\u00a0kg, 62.5\u00a0mg\r\ntwice daily; 12\u201319\u00a0kg, 125\u00a0mg twice daily; 20\u201329\u00a0kg, 187.5\u00a0mg twice\r\ndaily; 30\u201340\u00a0kg, 250\u00a0mg twice daily", "Lyme disease (see also section 5.1.1.3), adult and child over 12 years, 500\u00a0mg every\r\n12 hours for 14\u201321 days [unlicensed duration]; child 1 month\u201312 years see BNF for Children", "By intravenous infusion into larger\r\nproximal vein, adult and child over 12 years, 500\u00a0mg twice daily; child 1 month\u201312 years see BNF for Children", "Name[Klaricid XL\u00ae (Abbott) ] Tablets, m/r, yellow, clarithromycin 500\u00a0mg, net price 7-tab pack = \u00a36.46, 14-tab pack = \u00a312.71. \r\n    Label:\r\n    9, 21, 25Dose\u00a0500\u00a0mg once daily (doubled in severe infections) for 7\u201314\r\ndays"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid unless potential benefit\r\noutweighs risk"}]